# KH815 first-in-human study

Source: https://onco.cc/trials/nct06885645/  
OnCo record `nct06885645` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A planned early study of KH815 in people with advanced solid tumors. The registry still lists it as not yet recruiting, with no results posted.

## Summary

NCT06885645 is a first-in-human dose-escalation study of the dual-payload TROP2 ADC KH815. The ClinicalTrials.gov record last posted 3 April 2025 lists NOT_YET_RECRUITING, estimated enrollment of 30, an estimated start on 30 April 2025 and estimated primary completion on 30 June 2027. These dates remain estimates when checked 6 October 2026; no results or study locations are posted. The protocol excludes a history of interstitial lung disease/pneumonia or screening imaging on which it cannot be ruled out. Registered status does not confirm current availability or individual eligibility.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Registry id: NCT06885645
- Phase: 1
- Setting: Advanced or unresectable solid tumors after failure of, difficulty with, or unsuitability for standard therapies; measurable disease and ECOG performance status 0 or 1 required.
- Sponsor: Chengdu Kanghong Biotech Co., Ltd.

## Sources

- ClinicalTrials.gov NCT06885645: https://clinicaltrials.gov/study/NCT06885645

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [KH815](https://onco.cc/drugs/kh815/)

---
JSON: https://onco.cc/api/v1/entities/nct06885645.json